

# Zheng-Xiong Xi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/709456/publications.pdf>

Version: 2024-02-01

132  
papers

7,846  
citations

47006

47  
h-index

56724

83  
g-index

134  
all docs

134  
docs citations

134  
times ranked

6204  
citing authors

#	ARTICLE	IF	CITATIONS
1	Repeated cocaine administration upregulates CB2 receptor expression in striatal medium-spiny neurons that express dopamine D1 receptors in mice. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 876-888.	6.1	13
2	Elevation of Extracellular Glutamate by Blockade of Astrocyte Glutamate Transporters Inhibits Cocaine Reinforcement in Rats via a NMDA-GluN2B Receptor Mechanism. <i>Journal of Neuroscience</i> , 2022, 42, 2327-2343.	3.6	8
3	Involvement of the ghrelin system in the maintenance of oxycodone self-administration: converging evidence from endocrine, pharmacologic and transgenic approaches. <i>Molecular Psychiatry</i> , 2022, 27, 2171-2181.	7.9	9
4	Involvement of the ghrelin system in the maintenance and reinstatement of cocaine-motivated behaviors: a role of adrenergic action at peripheral $\alpha_1$ receptors. <i>Neuropsychopharmacology</i> , 2022, 47, 1449-1460.	5.4	13
5	Receptor mechanisms underlying the CNS effects of cannabinoids: CB1 receptor and beyond. <i>Advances in Pharmacology</i> , 2022, 93, 275-333.	2.0	8
6	Current Perspectives on Selective Dopamine D3 Receptor Antagonists/Partial Agonists as Pharmacotherapeutics for Opioid and Psychostimulant Use Disorders. <i>Current Topics in Behavioral Neurosciences</i> , 2022, , 157-201.	1.7	11
7	Therapeutic potential of PIMSR, a novel CB1 receptor neutral antagonist, for cocaine use disorder: evidence from preclinical research. <i>Translational Psychiatry</i> , 2022, 12, .	4.8	3
8	Modafinil and its structural analogs as atypical dopamine uptake inhibitors and potential medications for psychostimulant use disorder. <i>Current Opinion in Pharmacology</i> , 2021, 56, 13-21.	3.5	20
9	Progress in opioid reward research: From a canonical two-neuron hypothesis to two neural circuits. <i>Pharmacology Biochemistry and Behavior</i> , 2021, 200, 173072.	2.9	16
10	Dissecting the role of CB1 and CB2 receptors in cannabinoid reward versus aversion using transgenic CB1- and CB2-knockout mice. <i>European Neuropsychopharmacology</i> , 2021, 43, 38-51.	0.7	18
11	Beta-caryophyllene inhibits cocaine addiction-related behavior by activation of $PPAR_1$ and $PPAR_3$ : repurposing a FDA-approved food additive for cocaine use disorder. <i>Neuropsychopharmacology</i> , 2021, 46, 860-870.	5.4	19
12	New Drugs, Old Targets: Tweaking the Dopamine System to Treat Psychostimulant Use Disorders. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 609-628.	9.4	36
13	Increased novelty-induced locomotion, sensitivity to amphetamine, and extracellular dopamine in striatum of <i>Zdhc15</i> -deficient mice. <i>Translational Psychiatry</i> , 2021, 11, 65.	4.8	12
14	Optogenetic brain stimulation reward: A new procedure to re-evaluate the rewarding <i>versus</i> aversive effects of cannabinoids in dopamine transporter-Cre mice. <i>Addiction Biology</i> , 2021, 26, e13005.	2.6	19
15	Deletion of VGLUT2 in midbrain dopamine neurons attenuates dopamine and glutamate responses to methamphetamine in mice. <i>Pharmacology Biochemistry and Behavior</i> , 2021, 202, 173104.	2.9	8
16	Cannabinoid CB2 receptors are expressed in glutamate neurons in the red nucleus and functionally modulate motor behavior in mice. <i>Neuropharmacology</i> , 2021, 189, 108538.	4.1	20
17	Pharmacology in the age of circuit neuroscience: Illuminating the neural mechanisms of reward, drug use and addiction and enlightening the future of translational research. <i>Pharmacology Biochemistry and Behavior</i> , 2021, 206, 173187.	2.9	0
18	$\beta$ -caryophyllene, an FDA-Approved Food Additive, Inhibits Methamphetamine-Taking and Methamphetamine-Seeking Behaviors Possibly via CB2 and Non-CB2 Receptor Mechanisms. <i>Frontiers in Pharmacology</i> , 2021, 12, 722476.	3.5	12

#	ARTICLE	IF	CITATIONS
19	Effects of the selective dopamine D3 receptor antagonist PG01037 on morphine-induced hyperactivity and antinociception in mice. <i>Behavioural Brain Research</i> , 2021, 415, 113506.	2.2	12
20	Possible Receptor Mechanisms Underlying Cannabidiol Effects on Addictive-like Behaviors in Experimental Animals. <i>International Journal of Molecular Sciences</i> , 2021, 22, 134.	4.1	24
21	Synaptic Zn <sup>2+</sup> potentiates the effects of cocaine on striatal dopamine neurotransmission and behavior. <i>Translational Psychiatry</i> , 2021, 11, 570.	4.8	3
22	Identification of the Risk Genes Associated With Vulnerability to Addiction: Major Findings From Transgenic Animals. <i>Frontiers in Neuroscience</i> , 2021, 15, 811192.	2.8	6
23	Mitochondrial Clk1-iron-DAT regulation pathway: a possible new therapeutic target for methamphetamine use disorder. <i>Acta Pharmacologica Sinica</i> , 2021, , .	6.1	1
24	Cannabidiol inhibits sucrose self-administration by <sc>CB</sc>1 and <sc>CB</sc>2 receptor mechanisms in rodents. <i>Addiction Biology</i> , 2020, 25, e12783.	2.6	30
25	Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5-HT1A and TRPV1 receptor mechanisms. <i>Neuropharmacology</i> , 2020, 167, 107740.	4.1	75
26	Different receptor mechanisms underlying phytocannabinoidâ€•versus synthetic cannabinoidâ€•induced tetrad effects: Opposite roles of CB<sub>1</sub>/CB<sub>2</sub> versus GPR55 receptors. <i>British Journal of Pharmacology</i> , 2020, 177, 1865-1880.	5.4	36
27	Î²â€•caryophyllene, a dietary terpenoid, inhibits nicotine taking and nicotine seeking in rodents. <i>British Journal of Pharmacology</i> , 2020, 177, 2058-2072.	5.4	21
28	Dissecting the Role of GABA Neurons in the VTA<i>versus</i>SNr in Opioid Reward. <i>Journal of Neuroscience</i> , 2020, 40, 8853-8869.	3.6	61
29	Xie2-64, a novel CB2 receptor inverse agonist, reduces cocaine abuse-related behaviors in rodents. <i>Neuropharmacology</i> , 2020, 176, 108241.	4.1	13
30	(Â±)VK4â€•40, a novel dopamine D<sub>3</sub> receptor partial agonist, attenuates cocaine reward and relapse in rodents. <i>British Journal of Pharmacology</i> , 2020, 177, 4796-4807.	5.4	15
31	Modafinil potentiates cocaine self-administration by a dopamine-independent mechanism: possible involvement of gap junctions. <i>Neuropsychopharmacology</i> , 2020, 45, 1518-1526.	5.4	13
32	Neurochemical and behavioral comparisons of contingent and non-contingent methamphetamine exposure following binge or yoked long-access self-administration paradigms. <i>Psychopharmacology</i> , 2020, 237, 1989-2005.	3.1	19
33	Dopamine D3 receptor-based medication development for the treatment of opioid use disorder: Rationale, progress, and challenges. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 114, 38-52.	6.1	27
34	Betaâ€•caryophyllene, a Volatile Phytocannabinoid, Attenuates Cocaine Selfâ€•Administration and Relapse in Rats. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.5	0
35	Gap Junctions Modulate The Effects Of Modafinil On Cocaine Selfâ€•Administration Behavior In A Dopamineâ€•Independent Fashion In Rats. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.5	0
36	CB2 receptor antibody signal specificity: correlations with the use of partial CB2-knockout mice and anti-rat CB2 receptor antibodies. <i>Acta Pharmacologica Sinica</i> , 2019, 40, 398-409.	6.1	42

#	ARTICLE	IF	CITATIONS
37	Cannabinoid CB1 receptor neutral antagonist AM4113 inhibits heroin self-administration without depressive side effects in rats. <i>Acta Pharmacologica Sinica</i> , 2019, 40, 365-373.	6.1	37
38	Δ <sup>9</sup> -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence. <i>British Journal of Pharmacology</i> , 2019, 176, 4773-4784.	5.4	11
39	Investigation of Novel Primary and Secondary Pharmacophores and 3-Substitution in the Linking Chain of a Series of Highly Selective and Bitopic Dopamine D <sub>3</sub> Receptor Antagonists and Partial Agonists. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 9061-9077.	6.4	30
40	Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders. <i>CNS Drugs</i> , 2019, 33, 1001-1030.	5.9	40
41	Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine. <i>Neuropharmacology</i> , 2019, 158, 107609.	4.1	44
42	Translating the atypical dopamine uptake inhibitor hypothesis toward therapeutics for treatment of psychostimulant use disorders. <i>Neuropsychopharmacology</i> , 2019, 44, 1435-1444.	5.4	35
43	The highly selective dopamine D <sub>2</sub> antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents. <i>Neuropharmacology</i> , 2019, 158, 107597.	4.1	51
44	Mechanisms of cannabinoid CB2 receptor-mediated reduction of dopamine neuronal excitability in mouse ventral tegmental area. <i>EBioMedicine</i> , 2019, 42, 225-237.	6.1	44
45	Cannabinoid CB <sub>1</sub> and CB <sub>2</sub> receptor mechanisms underlie cannabis reward and aversion in rats. <i>British Journal of Pharmacology</i> , 2019, 176, 1268-1281.	5.4	54
46	Newly Developed Dopamine D <sub>3</sub> Receptor Antagonists, R-VK4-40 and R-VK4-116, Do Not Potentiate Cardiovascular Effects of Cocaine or Oxycodone in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 371, 602-614.	2.5	24
47	Identification of novel mouse and rat CB1R isoforms and in silico modeling of human CB1R for peripheral cannabinoid therapeutics. <i>Acta Pharmacologica Sinica</i> , 2019, 40, 387-397.	6.1	14
48	Dopamine D3R antagonist VK4-116 attenuates oxycodone self-administration and reinstatement without compromising its antinociceptive effects. <i>Neuropsychopharmacology</i> , 2019, 44, 1415-1424.	5.4	61
49	Progress in brain cannabinoid CB2 receptor research: From genes to behavior. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 98, 208-220.	6.1	139
50	Structurally Similar and Behaviorally Unique Modafinil Analogs as Potential Pharmacotherapeutics for Psychostimulant Use Disorder. <i>FASEB Journal</i> , 2019, 33, 664.6.	0.5	0
51	mGluR5 antagonism inhibits cocaine reinforcement and relapse by elevation of extracellular glutamate in the nucleus accumbens via a CB1 receptor mechanism. <i>Scientific Reports</i> , 2018, 8, 3686.	3.3	32
52	Discovery and development of varenicline for smoking cessation. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 671-683.	5.0	65
53	Genetic deletion of vesicular glutamate transporter in dopamine neurons increases vulnerability to MPTP-induced neurotoxicity in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E11532-E11541.	7.1	34
54	Deletion of the type 2 metabotropic glutamate receptor increases heroin abuse vulnerability in transgenic rats. <i>Neuropsychopharmacology</i> , 2018, 43, 2615-2626.	5.4	18

#	ARTICLE	IF	CITATIONS
55	Cocaine reward is reduced by decreased expression of receptor-type protein tyrosine phosphatase D (PTPRD) and by a novel PTPRD antagonist. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 11597-11602.	7.1	33
56	Genetic deletion of the dopamine D3 receptor increases vulnerability to heroin in mice. Neuropharmacology, 2018, 141, 11-20.	4.1	20
57	Beyond small-molecule SAR: Using the dopamine D3 receptor crystal structure to guide drug design. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY20-2.	0.0	0
58	Expression of functional cannabinoid CB <sub>2</sub> receptor in VTA dopamine neurons in rats. Addiction Biology, 2017, 22, 752-765.	2.6	117
59	The Novel Modafinil Analog, JJC8-016, as a Potential Cocaine Abuse Pharmacotherapeutic. Neuropsychopharmacology, 2017, 42, 1871-1883.	5.4	29
60	CB1 Receptor Activation on VgluT2-Expressing Glutamatergic Neurons Underlies $\Delta^9$ -Tetrahydrocannabinol ( $\Delta^9$ -THC)-Induced Aversive Effects in Mice. Scientific Reports, 2017, 7, 12315.	3.3	48
61	The novel dopamine D3 receptor antagonists/partial agonists CAB2-015 and BAK4-54 inhibit oxycodone-taking and oxycodone-seeking behavior in rats. Neuropharmacology, 2017, 126, 190-199.	4.1	50
62	Cannabinoid type 2 receptors in dopamine neurons inhibits psychomotor behaviors, alters anxiety, depression and alcohol preference. Scientific Reports, 2017, 7, 17410.	3.3	122
63	Deletion of Type 2 Metabotropic Glutamate Receptor Decreases Sensitivity to Cocaine Reward in Rats. Cell Reports, 2017, 20, 319-332.	6.4	28
64	Local Cues Establish and Maintain Region-Specific Phenotypes of Basal Ganglia Microglia. Neuron, 2017, 95, 341-356.e6.	8.1	325
65	CTDP-32476: A Promising Agonist Therapy for Treatment of Cocaine Addiction. Neuropsychopharmacology, 2017, 42, 682-694.	5.4	11
66	Methadone Usage, Misuse, and Addiction Processes. , 2016, , 399-406.		0
67	Cannabinoid Type 2 Receptors Mediate a Cell Type-Specific Plasticity in the Hippocampus. Neuron, 2016, 90, 795-809.	8.1	238
68	T394A Mutation at the $\mu$ Opioid Receptor Blocks Opioid Tolerance and Increases Vulnerability to Heroin Self-Administration in Mice. Journal of Neuroscience, 2016, 36, 10392-10403.	3.6	16
69	Highly Selective Dopamine D <sub>3</sub> Receptor (D <sub>3</sub> R) Antagonists and Partial Agonists Based on Eticlopride and the D <sub>3</sub> R Crystal Structure: New Leads for Opioid Dependence Treatment. Journal of Medicinal Chemistry, 2016, 59, 7634-7650.	6.4	73
70	Novel and High Affinity 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues as Atypical Dopamine Transporter Inhibitors. Journal of Medicinal Chemistry, 2016, 59, 10676-10691.	6.4	58
71	Aggregated single-walled carbon nanotubes attenuate the behavioural and neurochemical effects of methamphetamine in mice. Nature Nanotechnology, 2016, 11, 613-620.	31.5	51
72	Combination of Levo-Tetrahydropalmatine and Low Dose Naltrexone: A Promising Treatment for Prevention of Cocaine Relapse. Journal of Pharmacology and Experimental Therapeutics, 2016, 357, 248-257.	2.5	18

#	ARTICLE	IF	CITATIONS
73	R-Modafinil Attenuates Nicotine-Taking and Nicotine-Seeking Behavior in Alcohol-Preferring Rats. <i>Neuropsychopharmacology</i> , 2015, 40, 1762-1771.	5.4	16
74	Sigma-1 receptor mediates cocaine-induced transcriptional regulation by recruiting chromatin-remodeling factors at the nuclear envelope. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E6562-70.	7.1	95
75	High Affinity Dopamine D <sub>3</sub> Receptor (D <sub>3</sub> R)-Selective Antagonists Attenuate Heroin Self-Administration in Wild-Type but not D <sub>3</sub> R Knockout Mice. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 6195-6213.	6.4	45
76	Species Differences in Cannabinoid Receptor 2 and Receptor Responses to Cocaine Self-Administration in Mice and Rats. <i>Neuropsychopharmacology</i> , 2015, 40, 1037-1051.	5.4	110
77	A novel mGluR5 antagonist, MFZ 1017, inhibits cocaine-taking and cocaine-seeking behavior in rats. <i>Addiction Biology</i> , 2014, 19, 195-209.	2.6	34
78	Cannabinoid CB <sub>2</sub> receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E5007-15.	7.1	291
79	Blockade of D3 receptors by YQA14 inhibits cocaine's rewarding effects and relapse to drug-seeking behavior in rats. <i>Neuropharmacology</i> , 2014, 77, 398-405.	4.1	37
80	Fenobam sulfate inhibits cocaine-taking and cocaine-seeking behavior in rats: implications for addiction treatment in humans. <i>Psychopharmacology</i> , 2013, 229, 253-265.	3.1	33
81	Effects of metabotropic glutamate receptor ligands on male sexual behavior in rats. <i>Neuropharmacology</i> , 2013, 66, 373-381.	4.1	12
82	Blockade of dopamine D <sub>3</sub> receptors in the nucleus accumbens and central amygdala inhibits incubation of cocaine craving in rats. <i>Addiction Biology</i> , 2013, 18, 665-677.	2.6	83
83	Metabotropic glutamate 7 (mGlu7) receptor: A target for medication development for the treatment of cocaine dependence. <i>Neuropharmacology</i> , 2013, 66, 12-23.	4.1	18
84	Dopamine D3 receptor deletion or blockade attenuates cocaine-induced conditioned place preference in mice. <i>Neuropharmacology</i> , 2013, 72, 82-87.	4.1	35
85	Increased vulnerability to cocaine in mice lacking dopamine D <sub>3</sub> receptors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 17675-17680.	7.1	69
86	Cocaine-taking and cocaine-seeking behaviors in rats remain stable after systemic administration of GYKI 52466: A non-competitive AMPA receptor antagonist. <i>Neuroscience Letters</i> , 2012, 508, 106-109.	2.1	2
87	Medication Development for the Treatment of Cocaine Addiction – Progress at Preclinical and Clinical Levels. , 2012, , .		0
88	YQA14: a novel dopamine D <sub>3</sub> receptor antagonist that inhibits cocaine self-administration in rats and mice, but not in D <sub>3</sub> receptor knockout mice. <i>Addiction Biology</i> , 2012, 17, 259-273.	2.6	85
89	Brain cannabinoid CB2 receptors modulate cocaine's actions in mice. <i>Nature Neuroscience</i> , 2011, 14, 1160-1166.	14.8	358
90	Dopamine D3 receptor antagonist SB-277011A inhibits methamphetamine self-administration and methamphetamine-induced reinstatement of drug-seeking in rats. <i>European Journal of Pharmacology</i> , 2011, 659, 187-192.	3.5	57

#	ARTICLE	IF	CITATIONS
91	PG01037, a novel dopamine D <sub>3</sub> receptor antagonist, inhibits the effects of methamphetamine in rats. <i>Journal of Psychopharmacology</i> , 2011, 25, 263-273.	4.0	57
92	Gamma-vinyl GABA increases nonvesicular release of GABA and glutamate in the nucleus accumbens in rats via action on anion channels and GABA transporters. <i>Psychopharmacology</i> , 2010, 208, 511-519.	3.1	8
93	Oral administration of the NAALADase inhibitor GPI-5693 attenuates cocaine-induced reinstatement of drug-seeking behavior in rats. <i>European Journal of Pharmacology</i> , 2010, 627, 156-161.	3.5	24
94	Inhibition of NAALADase by 2-PPMPA attenuates cocaine-induced relapse in rats: a NAAG-mGluR2/3-mediated mechanism. <i>Journal of Neurochemistry</i> , 2010, 112, 564-576.	3.9	51
95	Activation of mGluR7s inhibits cocaine-induced reinstatement of drug-seeking behavior by a nucleus accumbens glutamate-mGluR2/3 mechanism in rats. <i>Journal of Neurochemistry</i> , 2010, 114, 1368-1380.	3.9	63
96	Preclinical pharmacology, efficacy, and safety of varenicline in smoking cessation and clinical utility in high risk patients. <i>Drug, Healthcare and Patient Safety</i> , 2010, 2010, 39.	2.5	19
97	Is Slow-Onset Long-Acting Monoamine Transport Blockade to Cocaine as Methadone is to Heroin? Implication for Anti-Addiction Medications. <i>Neuropsychopharmacology</i> , 2010, 35, 2564-2578.	5.4	26
98	N-acetylaspartylglutamate (NAAG) inhibits intravenous cocaine self-administration and cocaine-enhanced brain-stimulation reward in rats. <i>Neuropharmacology</i> , 2010, 58, 304-313.	4.1	45
99	Metabotropic Glutamate Receptor 7 Modulates the Rewarding Effects of Cocaine in Rats: Involvement of a Ventral Pallidal GABAergic Mechanism. <i>Neuropsychopharmacology</i> , 2009, 34, 1783-1796.	5.4	65
100	Lower glutamate levels in rostral anterior cingulate of chronic cocaine users – A 1H-MRS study using TE-averaged PRESS at 3T with an optimized quantification strategy. <i>Psychiatry Research - Neuroimaging</i> , 2009, 174, 171-176.	1.8	63
101	Attenuation of basal and cocaine-enhanced locomotion and nucleus accumbens dopamine in cannabinoid CB1-receptor-knockout mice. <i>Psychopharmacology</i> , 2009, 204, 1-11.	3.1	68
102	Mechanism-based medication development for the treatment of nicotine dependence. <i>Acta Pharmacologica Sinica</i> , 2009, 30, 723-739.	6.1	35
103	Species differences in cannabinoid receptor 2 ( <i>CNR2</i> gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands. <i>Genes, Brain and Behavior</i> , 2009, 8, 519-530.	2.2	214
104	The preferential dopamine D3 receptor antagonist S33138 inhibits cocaine reward and cocaine-triggered relapse to drug-seeking behavior in rats. <i>Neuropharmacology</i> , 2009, 56, 752-760.	4.1	49
105	Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of $\alpha 4\beta 2$ nicotinic receptors in rats. <i>Neuropharmacology</i> , 2009, 57, 60-66.	4.1	52
106	A single high dose of methamphetamine increases cocaine self-administration by depletion of striatal dopamine in rats. <i>Neuroscience</i> , 2009, 161, 392-402.	2.3	33
107	The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats. <i>Psychopharmacology</i> , 2008, 196, 533-542.	3.1	65
108	The metabotropic glutamate receptor 7 (mGluR7) allosteric agonist AMN082 modulates nucleus accumbens GABA and glutamate, but not dopamine, in rats. <i>Neuropharmacology</i> , 2008, 54, 542-551.	4.1	54



#	ARTICLE	IF	CITATIONS
109	Effects of gabapentin on cocaine self-administration, cocaine-triggered relapse and cocaine-enhanced nucleus accumbens dopamine in rats. <i>Drug and Alcohol Dependence</i> , 2008, 97, 207-215.	3.2	24
110	Gamma-vinyl GABA inhibits cocaine-triggered reinstatement of drug-seeking behavior in rats by a non-dopaminergic mechanism. <i>Drug and Alcohol Dependence</i> , 2008, 97, 216-225.	3.2	26
111	Cannabinoid CB1 Receptor Antagonists Attenuate Cocaine's Rewarding Effects: Experiments with Self-Administration and Brain-Stimulation Reward in Rats. <i>Neuropsychopharmacology</i> , 2008, 33, 1735-1745.	5.4	100
112	Hypothesis-Driven Medication Discovery for the Treatment of Psychostimulant Addiction. <i>Current Drug Abuse Reviews</i> , 2008, 1, 303-327.	3.4	68
113	Levo-tetrahydropalmatine inhibits cocaine's rewarding effects: Experiments with self-administration and brain-stimulation reward in rats. <i>Neuropharmacology</i> , 2007, 53, 771-782.	4.1	44
114	Pharmacological Actions of NGB 2904, a Selective Dopamine D 3 Receptor Antagonist, in Animal Models of Drug Addiction. <i>CNS Neuroscience &amp; Therapeutics</i> , 2007, 13, 240-259.	4.0	96
115	Cannabinoid CB1 Receptor Antagonist AM251 Inhibits Cocaine-Primed Relapse in Rats: Role of Glutamate in the Nucleus Accumbens. <i>Journal of Neuroscience</i> , 2006, 26, 8531-8536.	3.6	155
116	The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions. <i>International Journal of Neuropsychopharmacology</i> , 2006, 9, 585.	2.1	80
117	The Novel Dopamine D3 Receptor Antagonist NGB 2904 Inhibits Cocaine's Rewarding Effects and Cocaine-Induced Reinstatement of Drug-Seeking Behavior in Rats. <i>Neuropsychopharmacology</i> , 2006, 31, 1393-1405.	5.4	140
118	Selective dopamine D3receptor antagonism by SB-277011A attenuates cocaine reinforcement as assessed by progressive-ratio and variable-cost-variable-payoff fixed-ratio cocaine self-administration in rats. <i>European Journal of Neuroscience</i> , 2005, 21, 3427-3438.	2.6	133
119	Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: Role of dopamine D3 receptors. <i>Synapse</i> , 2005, 57, 17-28.	1.2	132
120	The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. <i>Brain Research Reviews</i> , 2005, 49, 77-105.	9.0	296
121	Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats. <i>Psychopharmacology</i> , 2004, 176, 57-65.	3.1	151
122	Opiate tolerance by heroin self-administration: An fMRI study in rat. <i>Magnetic Resonance in Medicine</i> , 2004, 52, 108-114.	3.0	37
123	Agents in Development for the Management of Cocaine Abuse. <i>Drugs</i> , 2004, 64, 1547-1573.	10.9	185
124	Attenuation of brain response to heroin correlates with the reinstatement of heroin-seeking in rats by fMRI. <i>NeuroImage</i> , 2004, 22, 1328-1335.	4.2	34
125	Inhibition of non-vesicular glutamate release by group III metabotropic glutamate receptors in the nucleus accumbens. <i>Journal of Neurochemistry</i> , 2003, 87, 1204-1212.	3.9	41
126	Opiate Self-Administration. , 2003, 84, 251-264.		1



#	ARTICLE	IF	CITATIONS
127	GABA Transmission in the Nucleus Accumbens Is Altered after Withdrawal from Repeated Cocaine. Journal of Neuroscience, 2003, 23, 3498-3505.	3.6	123
128	Group II Metabotropic Glutamate Receptors Modulate Extracellular Glutamate in the Nucleus Accumbens. Journal of Pharmacology and Experimental Therapeutics, 2002, 300, 162-171.	2.5	197
129	Modulation of Group II Metabotropic Glutamate Receptor Signaling by Chronic Cocaine. Journal of Pharmacology and Experimental Therapeutics, 2002, 303, 608-615.	2.5	171
130	The Origin and Neuronal Function of <i>In Vivo</i> Nonsynaptic Glutamate. Journal of Neuroscience, 2002, 22, 9134-9141.	3.6	531
131	GABAergic MECHANISMS OF OPIATE REINFORCEMENT. Alcohol and Alcoholism, 2002, 37, 485-494.	1.6	97
132	Mechanisms of Cannabinoid CB2 Receptor-Mediated Reduction of Dopamine Neuronal Excitability in Mouse Ventral Tegmental Area. SSRN Electronic Journal, 0, , .	0.4	0